EMEA public statement on the market withdrawal of Daclizumab (Zenapax)

Daclizumab (Zenapax), a¬†monoclonal antibody to the alpha subunit of the IL-2 receptor of T cells, has been withdrawn from the market in the European Union since Since 1 January 2009. According¬†to an EMEA press release issued 16 January 2009: On 26 February 1999, the European Commission granted a marketing authorisation valid throughout the European Union […]